Compare DRDB & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | DRDB | CTNM |
|---|---|---|
| Founded | 2024 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.5M | 328.1M |
| IPO Year | 2024 | 2024 |
| Metric | DRDB | CTNM |
|---|---|---|
| Price | $10.42 | $12.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 57.5K | ★ 171.0K |
| Earning Date | 01-01-0001 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $595.83 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.87 | $3.35 |
| 52 Week High | $10.47 | $15.25 |
| Indicator | DRDB | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 47.42 | 59.69 |
| Support Level | $10.43 | $10.42 |
| Resistance Level | $10.47 | $11.43 |
| Average True Range (ATR) | 0.01 | 0.83 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 9.09 | 68.45 |
Roman DBDR Acquisition Corp II is a blank check company.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.